Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Paul L. Nguyen, MD


Radiation Oncology

Make an Appointment

Physician

  • Genitourinary Clinical Center Director for Radiation Oncology
  • Senior Physician
  • Professor of Radiation Oncology, Harvard Medical School

Clinical Interests

  • Genitourinary malignancies
  • Prostate brachytherapy
  • Prostate cancer

Contact Information

  • Appointments617-732-7936
  • Office Phone Number617-732-7936
  • Fax617-394-2669

Bio

Dr. Paul Nguyen is an internationally-recognized expert in prostate cancer clinical care and research. He has published over 350 original research articles and has national leadership as the vice-chair of the ARS/ACR Appropriateness Criteria Committee for Prostate Cancer and Chair of the Program Committee for the 2019 ASTRO/SUO/ASCO Genitourinary Cancers Symposium. He is the Principal Investigator of the multi-center randomized FORMULA-509 trial and co-chair of the international randomized ENZARAD trial. He serves as the DF/BWCC Genitourinary Clinical Center Director for Radiation Oncology, Vice-Chair for Clinical Research in the Department of Radiation Oncology, and Professor at Harvard Medical School. He received his AB from Harvard College, MD from Harvard Medical School, and completed his residency at the Harvard Radiation Oncology Program where he served as chief resident.

Board Certification:

  • Radiation Oncology

Residency:

  • Harvard Radiation Oncology Program

Medical School:

  • Harvard Medical School

Research

Dr. Nguyen’s primary research expertise is the optimal use of systemic therapy with radiation for high-risk prostate cancer, side effects of androgen-deprivation therapy, and the genetic and molecular markers to optimize risk stratification and personalization of treatment for men with prostate cancer.  In addition he has published extensively in health services research and racial disparities in prostate cancer treatment and outcome.

Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiother Oncol. 2021 08; 161:241-250.
View in: PubMed

Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited. J Clin Oncol. 2021 Sep 01; 39(25):2845-2846.
View in: PubMed

Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol. 2021 06 03; 4(1):670.
View in: PubMed

Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. J Natl Cancer Inst. 2021 Jun 01; 113(6):719-726.
View in: PubMed

Association of Medicaid expansion and insurance status, cancer stage, treatment and mortality among patients with cervical cancer. Cancer Rep (Hoboken). 2021 May 02; e1407.
View in: PubMed

Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. Cancer. 2021 Jul 01; 127(13):2213-2221.
View in: PubMed

Clinical characterization of radiation-associated muscle-invasive bladder cancer. Urology. 2021 Aug; 154:208-214.
View in: PubMed

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 01; 7(4):544-552.
View in: PubMed

Financial worry and psychological distress among cancer survivors in the United States, 2013-2018. Support Care Cancer. 2021 Sep; 29(9):5523-5535.
View in: PubMed

Correlative analysis between two commercially available post-prostatectomy genomic tests. Prostate Cancer Prostatic Dis. 2021 06; 24(2):575-577.
View in: PubMed

Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304.
View in: PubMed

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 2021 03; 22(3):402-410.
View in: PubMed

Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma. JCO Oncol Pract. 2021 Feb 25; OP2000839.
View in: PubMed

Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions? Pract Radiat Oncol. 2021 Jul-Aug; 11(4):e426-e433.
View in: PubMed

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Apr 10; 39(11):1274-1305.
View in: PubMed

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021 Sep; 80(3):280-292.
View in: PubMed

Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urol Oncol. 2021 02; 39(2):130.e17-130.e24.
View in: PubMed

A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2021 03; 79(3):374-383.
View in: PubMed

Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1279-1285.
View in: PubMed

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 2020 12 01; 6(12):1912-1920.
View in: PubMed

Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. J Geriatr Oncol. 2021 06; 12(5):687-695.
View in: PubMed

The Case for Brachytherapy: Why It Deserves a Renaissance. Adv Radiat Oncol. 2021 Mar-Apr; 6(2):100605.
View in: PubMed

General and Health-Related Internet Use Among Cancer Survivors in the United States: A 2013-2018 Cross-Sectional Analysis. J Natl Compr Canc Netw. 2020 11; 18(11):1468-1475.
View in: PubMed

Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review. JAMA Oncol. 2020 Nov 01; 6(11):1793-1800.
View in: PubMed

Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. Brachytherapy. 2021 Jan-Feb; 20(1):1-9.
View in: PubMed

Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021 03 15; 109(4):953-963.
View in: PubMed

Less Is More During COVID 19. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):339.
View in: PubMed

Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. JAMA Oncol. 2020 10 01; 6(10):1630-1632.
View in: PubMed

Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer Prostatic Dis. 2021 06; 24(2):414-422.
View in: PubMed

Improving Diversity and Inclusion in the Post-Coronavirus Disease 2019 Era Through a Radiation Oncology Intensive Shadowing Experience (RISE). Adv Radiat Oncol. 2021 Jan-Feb; 6(1):100566.
View in: PubMed

Psychological Distress and Access to Mental Health Services Among Cancer Survivors: a National Health Interview Survey Analysis. J Gen Intern Med. 2020 Sep 15.
View in: PubMed

Racial Differences in Genomic Profiling of Prostate Cancer. N Engl J Med. 2020 09 10; 383(11):1083-1085.
View in: PubMed

Disparities in Mortality from Larynx Cancer: Implications for Reducing Racial Differences. Laryngoscope. 2021 04; 131(4):E1147-E1155.
View in: PubMed

Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96. Eur Urol. 2020 11; 78(5):e195.
View in: PubMed

NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):174-185.
View in: PubMed

Mental Distress and Mental Health Services Receipt in Foreign-Born Survivors of Cancer: a National Health Interview Survey Analysis. J Gen Intern Med. 2021 08; 36(8):2495-2498.
View in: PubMed

Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clin Genitourin Cancer. 2021 06; 19(3):246-254.e5.
View in: PubMed

Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology. 2020 Nov; 145:197-203.
View in: PubMed

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities. Prostate. 2020 09; 80(13):1128-1133.
View in: PubMed

Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol. 2020 09; 38(9):735.e9-735.e15.
View in: PubMed

To Radiate or Not to Radiate-The Challenges of Pelvic Reirradiation. Semin Radiat Oncol. 2020 Jul; 30(3):238-241.
View in: PubMed

Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):936-940.
View in: PubMed

Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 09; 78(3):327-332.
View in: PubMed

Prostate cancer management costs vary by disease stage at presentation. Prostate Cancer Prostatic Dis. 2020 12; 23(4):564-566.
View in: PubMed

Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020 09 10; 38(26):3024-3031.
View in: PubMed

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 05 01; 6(5):735-743.
View in: PubMed

Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. J Am Acad Dermatol. 2021 Jan; 84(1):168-172.
View in: PubMed

Local management of preinvasive and clinical T1-3 penile cancer: utilization of diverse treatment modalities. Future Oncol. 2020 May; 16(14):955-960.
View in: PubMed

Intermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol. 2020 06; 3(3):270-280.
View in: PubMed

Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer Prostatic Dis. 2020 12; 23(4):646-653.
View in: PubMed

Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
View in: PubMed

Changes in Length and Complexity of Clinical Practice Guidelines in Oncology, 1996-2019. JAMA Netw Open. 2020 03 02; 3(3):e200841.
View in: PubMed

Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. Am J Clin Oncol. 2020 03; 43(3):163-167.
View in: PubMed

Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. J Natl Cancer Inst. 2020 03 01; 112(3):229-237.
View in: PubMed

Validation of a subclassification for high-risk prostate cancer in a prospective cohort. Cancer. 2020 05 15; 126(10):2132-2138.
View in: PubMed

Trends, Quality, and Readability of Online Health Resources on Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):33-38.
View in: PubMed

Physician and facility drivers of spending variation in locoregional prostate cancer. Cancer. 2020 04 15; 126(8):1622-1631.
View in: PubMed

Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 04 01; 126(7):1407-1412.
View in: PubMed

Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352.
View in: PubMed

Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 02 15; 126(4):717-724.
View in: PubMed

An Update to Changing Patterns of Anal Carcinoma in the United States. Am J Clin Oncol. 2019 12; 42(12):887-897.
View in: PubMed

Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
View in: PubMed

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 02; 77(2):201-208.
View in: PubMed

Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. Eur Urol Oncol. 2021 Feb; 4(1):66-72.
View in: PubMed

Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. J Urol. 2019 11; 202(5):973-978.
View in: PubMed

United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis. 2020 03; 23(1):179-183.
View in: PubMed

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6721-6730.
View in: PubMed

Definitive and sustained increase in prostate cancer metastases in the United States. Urol Oncol. 2019 12; 37(12):988-990.
View in: PubMed

Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
View in: PubMed

Using Stereotactic Body Radiotherapy to Overcome the Radioresistant Reputation of Renal Cell Carcinoma. Eur Urol Oncol. 2019 09; 2(5):524-525.
View in: PubMed

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948.
View in: PubMed

Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):621-627.
View in: PubMed

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983.
View in: PubMed

Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 10 01; 125(19):3338-3346.
View in: PubMed

Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. J Am Coll Cardiol. 2019 06 18; 73(23):2976-2987.
View in: PubMed

Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019 07; 2(4):405-412.
View in: PubMed

Association of Treatment With 5a-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. JAMA Intern Med. 2019 06 01; 179(6):812-819.
View in: PubMed

Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. Cancer. 2019 09 15; 125(18):3164-3171.
View in: PubMed

Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072.
View in: PubMed

The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? Urol Oncol. 2019 09; 37(9):575.e9-575.e18.
View in: PubMed

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 May 01; 5(5):664-670.
View in: PubMed

Evolution of Radiation Oncology in Pakistan. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):11-16.
View in: PubMed

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Jul 15; 25(14):4290-4299.
View in: PubMed

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2020 01; 77(1):3-10.
View in: PubMed

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):778-789.
View in: PubMed

Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
View in: PubMed

Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
View in: PubMed

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019 03 01; 111(3):301-310.
View in: PubMed

Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. J Med Virol. 2019 07; 91(7):1288-1294.
View in: PubMed

Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU Int. 2019 07; 124(1):35-39.
View in: PubMed

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. JAMA. 2019 Feb 19; 321(7):704-706.
View in: PubMed

A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. Clin Genitourin Cancer. 2019 06; 17(3):e472-e481.
View in: PubMed

Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. Eur Urol Oncol. 2021 Apr; 4(2):327-330.
View in: PubMed

Postoperative Radiation Therapy in Localized Prostate Cancer: When, How Much, and How Fast? Int J Radiat Oncol Biol Phys. 2019 02 01; 103(2):289-292.
View in: PubMed

Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol. 2019 06; 75(6):1038-1040.
View in: PubMed

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
View in: PubMed

A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191.
View in: PubMed

Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy. 2019 Mar - Apr; 18(2):198-203.
View in: PubMed

Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clin Infect Dis. 2019 01 07; 68(2):247-255.
View in: PubMed

Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. Am J Gastroenterol. 2019 01; 114(1):80-88.
View in: PubMed

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457.
View in: PubMed

Reply to Partial gland therapy for prostate cancer. Cancer. 2019 03 01; 125(5):819-820.
View in: PubMed

Correction: Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. PLoS One. 2018; 13(12):e0209715.
View in: PubMed

Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review. Eur Urol. 2019 03; 75(3):464-476.
View in: PubMed

Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
View in: PubMed

Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. Eur Urol Oncol. 2019 05; 2(3):265-273.
View in: PubMed

Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. Am J Clin Oncol. 2018 Nov; 41(11):1062-1068.
View in: PubMed

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41.
View in: PubMed

Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. Dig Dis Sci. 2019 03; 64(3):698-707.
View in: PubMed

Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018 12 01; 315(6):E1185-E1193.
View in: PubMed

Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4027-4034.
View in: PubMed

Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2018 10; 41(10):953-959.
View in: PubMed

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018 Nov 10; 36(32):3251-3258.
View in: PubMed

'Reply to the letter to the editor 'Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer' by Yang et al.' by V. Conteduca, U. De giorgi and G. Lauletta. Ann Oncol. 2018 09 01; 29(9):2021-2022.
View in: PubMed

Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Eur Urol Oncol. 2019 03; 2(2):189-195.
View in: PubMed

Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
View in: PubMed

MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life. Radiother Oncol. 2018 12; 129(3):554-560.
View in: PubMed

The Long and Short of It: New Lessons on the Optimal Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer and Where We Need to Go From Here. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1014-1017.
View in: PubMed

Ductal carcinoma in situ on core needle biopsy only with no residual disease at surgery. Breast J. 2018 11; 24(6):971-975.
View in: PubMed

Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54. Eur Urol. 2018 11; 74(5):e112-e113.
View in: PubMed

Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer. 2018 09 01; 124(17):3528-3535.
View in: PubMed

Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study. Sci Rep. 2018 07 02; 8(1):9969.
View in: PubMed

Determining optimal eluter design by modeling physical dose enhancement in brachytherapy. Med Phys. 2018 Jun 15.
View in: PubMed

Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer. Clin Genitourin Cancer. 2018 08; 16(4):313-317.
View in: PubMed

Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):34-43.
View in: PubMed

Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers. Eur Urol Oncol. 2018 05; 1(1):1-2.
View in: PubMed

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):3-18.
View in: PubMed

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clin Cancer Res. 2018 08 15; 24(16):3908-3916.
View in: PubMed

Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. Sci Rep. 2018 05 08; 8(1):7164.
View in: PubMed

Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy. Cancer. 2018 07 15; 124(14):2939-2947.
View in: PubMed

Prostate Cancer - Local Treatment after Radiorecurrence: Surgery - Back to the future? Int Braz J Urol. 2018 May-Jun; 44(3):433-434.
View in: PubMed

Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. PLoS One. 2018; 13(4):e0196452.
View in: PubMed

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. J Endocr Soc. 2018 May 01; 2(5):485-496.
View in: PubMed

Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
View in: PubMed

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):883-888.
View in: PubMed

Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. Am J Clin Oncol. 2018 04; 41(4):409-415.
View in: PubMed

In Reply to Ong et al. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1295.
View in: PubMed

Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523.
View in: PubMed

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905.
View in: PubMed

Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials. JAMA Oncol. 2018 Mar 01; 4(3):413-414.
View in: PubMed

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154.
View in: PubMed

Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol. 2018 02 01; 29(2):386-391.
View in: PubMed

Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
View in: PubMed

Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386.
View in: PubMed

Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e96-e97.
View in: PubMed

Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis. Urology. 2018 04; 114:155-162.
View in: PubMed

The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. Eur Urol Focus. 2019 05; 5(3):474-481.
View in: PubMed

Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. J Urol. 2018 06; 199(6):1510-1517.
View in: PubMed

Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 04; 36(4):157.e15-157.e20.
View in: PubMed

Optimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer. Urol Oncol. 2017 Dec 15.
View in: PubMed

Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 03 15; 124(6):1141-1149.
View in: PubMed

Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol. 2018 07; 74(1):107-114.
View in: PubMed

Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technol Cancer Res Treat. 2017 12; 16(6):1194-1201.
View in: PubMed

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 12 01; 3(12):1663-1672.
View in: PubMed

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 02 20; 36(6):581-590.
View in: PubMed

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer. 2018 06; 16(3):226-234.
View in: PubMed

Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e100-e101.
View in: PubMed

More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int. 2018 05; 38(5):895-902.
View in: PubMed

Approach to the Patient with High-Risk Prostate Cancer. Urol Clin North Am. 2017 Nov; 44(4):635-645.
View in: PubMed

Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer. 2018 02 15; 124(4):752-759.
View in: PubMed

Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. J Surg Educ. 2018 Mar - Apr; 75(2):434-441.
View in: PubMed

Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018 02; 55(2):307-317.e1.
View in: PubMed

Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64.
View in: PubMed

Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):53-58.
View in: PubMed

Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. Eur Urol. 2018 Mar; 73(3):452-461.
View in: PubMed

Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017 Dec 15; 123(24):4832-4840.
View in: PubMed

Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urol Oncol. 2017 11; 35(11):664.e1-664.e9.
View in: PubMed

Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451.
View in: PubMed

Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):904-911.
View in: PubMed

Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. Int J Urol. 2017 10; 24(10):743-748.
View in: PubMed

A novel approach to an automated needle insertion in brachytherapy procedures. Med Biol Eng Comput. 2018 Feb; 56(2):273-287.
View in: PubMed

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2018 02; 73(2):156-165.
View in: PubMed

The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. J Urol. 2017 12; 198(6):1295-1300.
View in: PubMed

Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol. 2018 02; 73(2):262-270.
View in: PubMed

Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. Curr Urol Rep. 2017 Jul; 18(7):55.
View in: PubMed

The evolution of brachytherapy for prostate cancer. Nat Rev Urol. 2017 Jun 30; 14(7):415-439.
View in: PubMed

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76.
View in: PubMed

Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. Eur Urol. 2018 01; 73(1):11-20.
View in: PubMed

Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer. 2017 09 01; 141(5):933-944.
View in: PubMed

Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 09; 35(9):542.e25-542.e32.
View in: PubMed

Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017 11; 72(5):845-852.
View in: PubMed

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104.
View in: PubMed

Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. Prostate Int. 2017 Sep; 5(3):89-94.
View in: PubMed

Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
View in: PubMed

Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma. J Clin Gastroenterol. 2017 Apr; 51(4):384-390.
View in: PubMed

Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. Eur Urol. 2017 11; 72(5):712-735.
View in: PubMed

Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017 09; 20(3):259-264.
View in: PubMed

ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):437-454.
View in: PubMed

National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343.
View in: PubMed

Racial Disparities in Prostate Cancer Outcome among Prostate-Specific Antigen Screening Eligible Populations in the United States. Ann Oncol. 2017 Feb 08.
View in: PubMed

Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore). 2017 Feb; 96(6):e6128.
View in: PubMed

ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol. 2017 02; 40(1):1-10.
View in: PubMed

A Monte Carlo study of I-125 prostate brachytherapy with gold nanoparticles: dose enhancement with simultaneous rectal dose sparing via radiation shielding. Phys Med Biol. 2017 03 07; 62(5):1935-1948.
View in: PubMed

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 06; 20(2):186-192.
View in: PubMed

Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):140-147.
View in: PubMed

Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):726-732.
View in: PubMed

Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 05 01; 123(9):1536-1544.
View in: PubMed

ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276.
View in: PubMed

Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3.
View in: PubMed

ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):62-84.
View in: PubMed

Value of Extra-Early Initiation of Salvage Radiation for Increasing Prostate-Specific Antigen After Prostatectomy. J Clin Oncol. 2016 Oct 20; 34(30):3597-3599.
View in: PubMed

Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17(11):1612-1620.
View in: PubMed

Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
View in: PubMed

Optimization of the Radiation Management of High-Risk Prostate Cancer. Semin Radiat Oncol. 2017 01; 27(1):43-49.
View in: PubMed

Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. J Urol. 2017 02; 197(2):363-368.
View in: PubMed

Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700.
View in: PubMed

The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):321-6.
View in: PubMed

The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):368-73.
View in: PubMed

Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urol Oncol. 2017 02; 35(2):76-85.
View in: PubMed

Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):624-8.
View in: PubMed

Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterol. 2016; 3(1):e000107.
View in: PubMed

National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377.
View in: PubMed

Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98.
View in: PubMed

Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol. 2016 09 20; 34(27):3267-75.
View in: PubMed

The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. Brachytherapy. 2016 Nov - Dec; 15(6):701-706.
View in: PubMed

Recent relocation and decreased survival following a cancer diagnosis. Prev Med. 2016 08; 89:245-250.
View in: PubMed

Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice? Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):313-317.
View in: PubMed

Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer. 2016 08 15; 122(16):2496-504.
View in: PubMed

The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Prev Med. 2016 08; 89:140-145.
View in: PubMed

Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
View in: PubMed

Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016 06 01; 34(16):1905-12.
View in: PubMed

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016 07 10; 34(20):2325-32.
View in: PubMed

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016 Apr; 2(4):471-80.
View in: PubMed

Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8.
View in: PubMed

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016 Apr; 2(4):500-7.
View in: PubMed

Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. Eur Urol Focus. 2016 Dec; 2(5):532-539.
View in: PubMed

ACR Appropriateness Criteria Renal Cell Carcinoma Staging. J Am Coll Radiol. 2016 May; 13(5):518-25.
View in: PubMed

Rethinking the Balance of Risk and Benefit of Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):975-7.
View in: PubMed

High-Dose-Rate Monotherapy for Localized Prostate Cancer-What More Will It Take to Make This a Standard Therapy? Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):655-6.
View in: PubMed

National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12.
View in: PubMed

Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis. 2016 06; 19(2):197-201.
View in: PubMed

Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Dis Colon Rectum. 2016 Mar; 59(3):187-93.
View in: PubMed

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6.
View in: PubMed

Data on Medicare eligibility and cancer screening utilization. Data Brief. 2016 Jun; 7:679-81.
View in: PubMed

Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer. Int J Urol. 2016 Apr; 23(4):305-11.
View in: PubMed

The impact of Medicare eligibility on cancer screening behaviors. Prev Med. 2016 Apr; 85:47-52.
View in: PubMed

Editorial comment. Urology. 2016 Jan; 87:152.
View in: PubMed

Feasibility of brachytherapy as monotherapy for high-volume, low-risk prostate cancer. J Cancer Res Ther. 2016 Jan-Mar; 12(1):406-10.
View in: PubMed

Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
View in: PubMed

Asian Americans and prostate cancer: A nationwide population-based analysis. Urol Oncol. 2016 May; 34(5):233.e7-15.
View in: PubMed

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
View in: PubMed

Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90.
View in: PubMed

The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1777-86.
View in: PubMed

Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures: Results From the National Surgical Quality Improvement Program. Ann Surg. 2015 Dec; 262(6):955-64.
View in: PubMed

A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiat Oncol. 2015 Nov 25; 10:243.
View in: PubMed

Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. J Urol. 2016 04; 195(4 Pt 1):913-8.
View in: PubMed

Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA. 2015 Nov 17; 314(19):2077-9.
View in: PubMed

Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9.
View in: PubMed

Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22.
View in: PubMed

Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer. Brachytherapy. 2015 Nov-Dec; 14(6):773-80.
View in: PubMed

Development of a standard survivorship care plan template for radiation oncologists. Pract Radiat Oncol. 2016 Jan-Feb; 6(1):57-65.
View in: PubMed

Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32.
View in: PubMed

Suicide and accidental deaths among patients with non-metastatic prostate cancer. BJU Int. 2016 Aug; 118(2):286-97.
View in: PubMed

Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer. 2016 Jan 01; 122(1):78-83.
View in: PubMed

Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2015 Sep; 13(9):1131-8.
View in: PubMed

Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85.
View in: PubMed

Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urol Oncol. 2015 Dec; 33(12):503.e7-15.
View in: PubMed

Population-based assessment of determining predictors for quality of prostate cancer surveillance. Cancer. 2015 Dec 01; 121(23):4150-7.
View in: PubMed

Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17.
View in: PubMed

Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101.
View in: PubMed

Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. Radiat Oncol. 2015 Jul 30; 10:155.
View in: PubMed

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35.
View in: PubMed

Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged =66 years. Eur J Surg Oncol. 2015 Nov; 41(11):1529-39.
View in: PubMed

Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology. 2015 Jul; 86(1):35-40.
View in: PubMed

Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 2015 Dec; 13(6):525-30.e1-3.
View in: PubMed

An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. BJU Int. 2015 Dec; 116(6):911-9.
View in: PubMed

Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8.
View in: PubMed

ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer J. 2015 May 22; 5:e315.
View in: PubMed

High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):229-36.
View in: PubMed

Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015 Jul; 33(7):330.e19-25.
View in: PubMed

Shared decision making and use of decision AIDS for localized prostate cancer : perceptions from radiation oncologists and urologists. JAMA Intern Med. 2015 May; 175(5):792-9.
View in: PubMed

High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015 Jul; 26(7):1390-5.
View in: PubMed

Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. J Am Heart Assoc. 2015 Apr 20; 4(4).
View in: PubMed

A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015 Jul; 26(7):1396-401.
View in: PubMed

Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6.
View in: PubMed

Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Aug; 95(2):251-63.
View in: PubMed

Open-source image registration for MRI-TRUS fusion-guided prostate interventions. Int J Comput Assist Radiol Surg. 2015 Jun; 10(6):925-34.
View in: PubMed

Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. J Natl Cancer Inst. 2015 Jun; 107(6):djv054.
View in: PubMed

The blue light-dependent phosphorylation of the CCE domain determines the photosensitivity of Arabidopsis CRY2. Mol Plant. 2015 04; 8(4):631-43.
View in: PubMed

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906.
View in: PubMed

Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9.
View in: PubMed

Brachytherapy: where has it gone? J Clin Oncol. 2015 Mar 20; 33(9):980-2.
View in: PubMed

Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology. 2015 Feb; 85(2):343-9.
View in: PubMed

Potential for information and communication technologies to catalyze global collaborations in radiation oncology. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):444-7.
View in: PubMed

Radiation therapy for node-positive prostate cancer: it's time for a randomized trial. Oncology (Williston Park). 2015 Feb; 29(2):116-7.
View in: PubMed

Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
View in: PubMed

GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clin Genitourin Cancer. 2015 Aug; 13(4):370-377.e1.
View in: PubMed

Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015 Jan; 13(1):61-8.
View in: PubMed

Toward personalizing the use of androgen deprivation therapy to maximize benefit and minimize harm. Eur Urol. 2015 Sep; 68(3):397-8.
View in: PubMed

Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015 May; 94(2):228-37.
View in: PubMed

National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. Clin Genitourin Cancer. 2015 Jun; 13(3):e167-72.
View in: PubMed

Brachytherapy application with in situ dose painting administered by gold nanoparticle eluters. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):385-92.
View in: PubMed

ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6.
View in: PubMed

Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406.
View in: PubMed

Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Mar; 93(3):257-76.
View in: PubMed

The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015 Jan; 33(1):17.e9-17.e18.
View in: PubMed

Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65.
View in: PubMed

Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. Eur Urol. 2015 Jul; 68(1):32-9.
View in: PubMed

The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2015 Mar; 18(1):38-42.
View in: PubMed

Independent brachytherapy plan verification software: improving efficacy and efficiency. Radiother Oncol. 2014 Dec; 113(3):420-4.
View in: PubMed

Improving the efficiency of a block schedule for treatment planning simulation in a radiation oncology department. J Clin Oncol. 2014 Oct 20; 32(30_suppl):158.
View in: PubMed

Incidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282.
View in: PubMed

Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13.
View in: PubMed

Variation in pelvic lymph node dissection among patients undergoing radical prostatectomy by hospital characteristics and surgical approach: results from the National Cancer Database. J Urol. 2015 Mar; 193(3):820-5.
View in: PubMed

Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol. 2014 Sep 09; 9:200.
View in: PubMed

Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol. 2015 Jan; 22(1):89-95.
View in: PubMed

Mental health outcomes in elderly men with prostate cancer. Urol Oncol. 2014 Nov; 32(8):1333-40.
View in: PubMed

Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May; 67(5):825-36.
View in: PubMed

Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34.
View in: PubMed

The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9.
View in: PubMed

Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care. 2014 Jul; 52(7):579-85.
View in: PubMed

Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clin Genitourin Cancer. 2015 Feb; 13(1):e1-6.
View in: PubMed

Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92.
View in: PubMed

Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol. 2014 Dec; 192(6):1650-6.
View in: PubMed

Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov; 92(2):123-32.
View in: PubMed

Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014 Jul 01; 32(19):2025-30.
View in: PubMed

WE-A-17A-03: Catheter Digitization in High-Dose-Rate Brachytherapy with the Assistance of An Electromagnetic (EM) Tracking System. Med Phys. 2014 Jun; 41(6):487-488.
View in: PubMed

ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
View in: PubMed

The role of radical prostatectomy and lymph node dissection in the treatment of young men with high-grade node-positive prostate cancer: less is more--the benefits of surgery do not yet outweigh potential harms. Oncology (Williston Park). 2014 Jun; 28(6):523, 525.
View in: PubMed

Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9.
View in: PubMed

Response to Drs Rogers, Hayes, and Demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
View in: PubMed

Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8.
View in: PubMed

Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91.
View in: PubMed

Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95.
View in: PubMed

Refusal of curative radiation therapy and surgery among patients with cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):756-64.
View in: PubMed

Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol. 2014 May 10; 32(14):1419-26.
View in: PubMed

Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21.
View in: PubMed

Perceptions of radiation oncologists and urologists on sources and type of evidence to inform prostate cancer treatment decisions. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):277-83.
View in: PubMed

Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. BMJ Open. 2014 Mar 23; 4(3):e003921.
View in: PubMed

Placement of empty catheters for an HDR-emulating LDR prostate brachytherapy technique: comparison to standard intraoperative planning. Brachytherapy. 2014 Jul-Aug; 13(4):375-9.
View in: PubMed

Population-based comparative effectiveness of salvage radical prostatectomy vs cryotherapy. Urology. 2014 Mar; 83(3):653-7.
View in: PubMed

Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):163-9.
View in: PubMed

Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014 May 15; 120(10):1532-9.
View in: PubMed

Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study. Ann Oncol. 2014 May; 25(5):979-86.
View in: PubMed

Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer. 2014; 2014:912943.
View in: PubMed

Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. Eur Urol. 2014 Oct; 66(4):666-72.
View in: PubMed

Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014 May; 113(5b):E67-74.
View in: PubMed

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. 2014 Dec; 66(6):1125-32.
View in: PubMed

Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med. 2014 Apr; 11(4):1063-1070.
View in: PubMed

A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU Int. 2014 May; 113(5b):E106-11.
View in: PubMed

Population-based determinants of radical prostatectomy operative time. BJU Int. 2014 May; 113(5b):E112-8.
View in: PubMed

Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract. 2014 Mar; 10(2):107-12.
View in: PubMed

Cryptochrome-mediated light responses in plants. Enzymes. 2014; 35:167-89.
View in: PubMed

The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis. J Urol. 2014 Jun; 191(6):1678-84.
View in: PubMed

ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
View in: PubMed

Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Urol Oncol. 2014 Apr; 32(3):303-8.
View in: PubMed

Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer. 2014 Mar 15; 120(6):824-32.
View in: PubMed

Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72.
View in: PubMed

Novel use of a hydrogel spacer permits reirradiation in otherwise incurable recurrent gynecologic cancers. J Clin Oncol. 2013 Dec 01; 31(34):e446-7.
View in: PubMed

Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer. 2014 Jan 15; 120(2):238-43.
View in: PubMed

PSA screening: the case in favor. Oncology (Williston Park). 2013 Oct; 27(10):980, 982.
View in: PubMed

Marital status and survival in patients with cancer. J Clin Oncol. 2013 Nov 01; 31(31):3869-76.
View in: PubMed

Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol. 2013 Dec; 115(3):411-9.
View in: PubMed

Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes. Brachytherapy. 2014 Mar-Apr; 13(2):152-6.
View in: PubMed

Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology. 2013 Oct; 82(4):807-12.
View in: PubMed

Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. Semin Radiat Oncol. 2013 Jul; 23(3):222-34.
View in: PubMed

The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014 Oct; 66(4):732-51.
View in: PubMed

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer. 2013 Jun 25; 108(12):2478-84.
View in: PubMed

Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014 Mar; 35(10):612-23.
View in: PubMed

Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol. 2013 Aug; 24(8):2092-7.
View in: PubMed

Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):415-21.
View in: PubMed

Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer. 2013 Aug 01; 119(15):2771-7.
View in: PubMed

Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int. 2013 Jun; 111(8):1208-14.
View in: PubMed

Androgen-deprivation therapy and cardiovascular harm: let's not throw out the baby with the bathwater. Eur Urol. 2014 Apr; 65(4):710-2.
View in: PubMed

Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int. 2013 Aug; 112(4):E273-80.
View in: PubMed

Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate. J Clin Oncol. 2013 Feb 20; 31(6_suppl):161.
View in: PubMed

Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):2.
View in: PubMed

Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55.
View in: PubMed

Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials. J Clin Oncol. 2013 Feb 20; 31(6_suppl):353.
View in: PubMed

Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):232.
View in: PubMed

Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors. J Clin Oncol. 2013 Feb 20; 31(6_suppl):347.
View in: PubMed

Location of local recurrence after MRI-guided partial prostate brachytherapy targeting only the peripheral zone: Implications for focal therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):149.
View in: PubMed

Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):82.
View in: PubMed

A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
View in: PubMed

ACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance. J Am Coll Radiol. 2013 Feb; 10(2):83-92.
View in: PubMed

Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81(1):130-4.
View in: PubMed

Androgen deprivation for prostate cancer: when and how, the good and the bad. Am Soc Clin Oncol Educ Book. 2013.
View in: PubMed

Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol. 2013 Jun; 189(6):2092-8.
View in: PubMed

Certificate of need programs, intensity modulated radiation therapy use and the cost of prostate cancer care. J Urol. 2013 Jan; 189(1):75-9.
View in: PubMed

Harms versus benefits with duration of androgen suppression. Lancet Oncol. 2012 Dec; 13(12):1182-3.
View in: PubMed

Influence of surgeon and hospital volume on radical prostatectomy costs. J Urol. 2012 Dec; 188(6):2198-202.
View in: PubMed

Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol. 2013 Mar; 20(3):811-8.
View in: PubMed

Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol. 2012 Oct; 188(4):1151-6.
View in: PubMed

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6.
View in: PubMed

Morbidity and costs of salvage vs. primary radical prostatectomy in older men. Urol Oncol. 2013 Nov; 31(8):1477-82.
View in: PubMed

Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU Int. 2012 Nov; 110(9):1252-6.
View in: PubMed

High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy. 2013 Jan-Feb; 12(1):77-83.
View in: PubMed

Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. BJU Int. 2012 Dec; 110(11):1690-5.
View in: PubMed

Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73.
View in: PubMed

Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012 Jun; 61(6):1239-44.
View in: PubMed

Hospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy. J Urol. 2012 May; 187(5):1632-7.
View in: PubMed

Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352.
View in: PubMed

Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):383-9.
View in: PubMed

Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone. J Clin Oncol. 2012 Feb 10; 30(5_suppl):38.
View in: PubMed

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131.
View in: PubMed

Impact of race on prostate cancer selection and cause-specific mortality: A SEER database analysis. J Clin Oncol. 2012 Feb 10; 30(5_suppl):248.
View in: PubMed

Variability in prostate volume as determined by MRI versus ultrasound and its impact on treatment recommendations for patients with favorable-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):249.
View in: PubMed

Effect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):176.
View in: PubMed

Long-term results of MRI-guided partial prostate brachytherapy for favorable-risk prostate cancer: Implications for focal therapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):114.
View in: PubMed

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012 Jun; 61(6):1119-28.
View in: PubMed

Two solutions for registration of ultrasound to MRI for image-guided prostate interventions. Annu Int Conf IEEE Eng Med Biol Soc. 2012; 2012:1129-32.
View in: PubMed

Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. BJU Int. 2012 Jul; 110(2 Pt 2):E92-8.
View in: PubMed

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011 Dec 07; 306(21):2359-66.
View in: PubMed

Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):21-5.
View in: PubMed

Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2012 Jul; 110(2):201-5.
View in: PubMed

Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):172-178.
View in: PubMed

Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011 Oct 10; 29(29):3885-91.
View in: PubMed

Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer. 2012 Mar 01; 118(5):1260-7.
View in: PubMed

Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011 Sep; 186(3):865-72.
View in: PubMed

Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):1411-6.
View in: PubMed

Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):1185-91.
View in: PubMed

Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol. 2011 Sep; 60(3):536-47.
View in: PubMed

Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology. 2011 Jul; 78(1):93-8.
View in: PubMed

Overuse of imaging for staging low risk prostate cancer. J Urol. 2011 May; 185(5):1645-9.
View in: PubMed

Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011 Apr 20; 29(12):1517-24.
View in: PubMed

Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer. 2011 Nov 01; 117(21):4846-54.
View in: PubMed

Linear accelerator-based stereotactic radiosurgery for brainstem metastases: the Dana-Farber/Brigham and Women's Cancer Center experience. J Neurooncol. 2011 Sep; 104(2):553-7.
View in: PubMed

Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.
View in: PubMed

The debate over prostate cancer screening guidelines. Virtual Mentor. 2011 Jan 01; 13(1):10-5.
View in: PubMed

Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011 Jun; 22(6):1404-1412.
View in: PubMed

Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan; 185(1):116-20.
View in: PubMed

Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):928-37.
View in: PubMed

Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer. 2011 Jan 15; 117(2):406-13.
View in: PubMed

Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology. 2011 Feb; 77(2):402-6.
View in: PubMed

Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology. 2010 Nov; 76(5):1201-5.
View in: PubMed

Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
View in: PubMed

Deciding which patients to treat with salvage radiotherapy after prostatectomy. Oncology (Williston Park). 2010 Jul; 24(8):705, 711.
View in: PubMed

Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1318-22.
View in: PubMed

Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010 Apr 15; 116(8):1887-92.
View in: PubMed

Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010 Apr; 6(4):551-62.
View in: PubMed

Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol. 2010 May; 183(5):1798-802.
View in: PubMed

The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22.
View in: PubMed

Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1081-5.
View in: PubMed

The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):188-96.
View in: PubMed

Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5.
View in: PubMed

Editorial comment. J Urol. 2010 Mar; 183(3):989.
View in: PubMed

Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1046-52.
View in: PubMed

Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. J Clin Oncol. 2009 Dec 10; 27(35):6000-5.
View in: PubMed

Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol. 2009 May 20; 27(15_suppl):5129.
View in: PubMed

The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol. 2011 May-Jun; 29(3):302-8.
View in: PubMed

Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy. 2009 Oct-Dec; 8(4):345-52.
View in: PubMed

Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):337-41.
View in: PubMed

Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys. 2009 May 01; 74(1):104-9.
View in: PubMed

Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer. 2008 Dec 01; 113(11):3146-52.
View in: PubMed

Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88(12):1340-8.
View in: PubMed

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008 Nov; 9(11):1039-47.
View in: PubMed

Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):659-64.
View in: PubMed

Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? Oncology (Williston Park). 2008 Jun; 22(7):748-54; discussion 754, 757.
View in: PubMed

The association between overexpression of skp2 and the risk of recurrence following prostatectomy. J Clin Oncol. 2008 May 20; 26(15_suppl):11052.
View in: PubMed

The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol (Oxf). 2008 May; 14(5):195-201.
View in: PubMed

Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol. 2008 Apr 20; 26(12):2055-6; author reply 2056-7.
View in: PubMed

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008 May 10; 26(14):2373-8.
View in: PubMed

Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007 Oct 01; 110(7):1417-28.
View in: PubMed

Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer. 2007 Oct 01; 110(7):1485-92.
View in: PubMed

High-dose external beam radiation for localized prostate cancer: current status and future challenges. Cancer J. 2007 Sep-Oct; 13(5):295-301.
View in: PubMed

Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology. 2007 Aug; 70(2):288-93.
View in: PubMed

Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):444-53.
View in: PubMed

A placebo-controlled trial of etanercept, a tumor necrosis factor (TNF) inhibitor, in patients with the cancer anorexia/weight loss syndrome. North Central Cancer Treatment Group (NCCTG) trial N00C1. J Clin Oncol. 2006 Jun 20; 24(18_suppl):8534.
View in: PubMed

The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer. 2005 May 15; 103(10):2053-9.
View in: PubMed

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005 Mar 01; 23(7):1507-13.
View in: PubMed

The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med. 2004 Jul 26; 164(14):1557-60.
View in: PubMed

The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4503.
View in: PubMed

The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol. 2004 Jul-Aug; 22(4):295-9.
View in: PubMed

Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):400-5.
View in: PubMed

Increased lymphoblast-like cells following umbilical cord blood stem cell transplantation do not predict recurrent acute leukemia. Leukemia. 2002 Oct; 16(10):2171-2.
View in: PubMed

Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp Hematol. 1999 Oct; 27(10):1519-27.
View in: PubMed

Can pathology residents be trained to perform adequate bone marrow biopsies? Acad Med. 1999 Apr; 74(4):452.
View in: PubMed

False-negative rates of tumor metastases in the histologic examination of bone marrow. Mod Pathol. 1999 Jan; 12(1):29-32.
View in: PubMed

Research Departments:

Support My Research

Location

Brigham and Women's Hospital
75 Francis Street
Boston, MA 02215
Get Directions

Ratings

Top